Stay updated with breaking news from Invitae. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com downgraded shares of Invitae (NYSE:NVTA – Free Report) from a hold rating to a sell rating in a report published on Saturday. Other research analysts have also issued research reports about the stock. Piper Sandler lowered their price objective on shares of Invitae to $1.50 and set an underweight rating on the stock in […] ....
The U.S. Food and Drug Administration granted de novo marketing authorization for Invitae's Common Hereditary Cancers Panel, an in vitro diagnostic test to help detect dozens of cancer types. ....
The FDA awarded marketing authorization for a new Invitae test that uses next-generation sequencing to assess multiple genes to identify variants indicating a person’s predisposition for certain cancers. The regulatory action creates a new regulatory classification making Invitae’s test the predicate device for future cancer tests. ....
The U.S. Food and Drug Administration granted de novo marketing authorization for the Invitae Common Hereditary Cancers Panel, an in vitro diagnostic test that can help detect hundreds of genetic variants associated with an elevated risk of developing certain cancers. The test can also help identify potentially cancer-associated hereditary variants in individuals with already-diagnosed cancer. The test, which is the first of its kind to be granted FDA marketing authorization, evaluates DNA. ....
StockNews.com downgraded shares of Invitae (NYSE:NVTA – Free Report) from a hold rating to a sell rating in a research report report published on Thursday. NVTA has been the subject of several other research reports. Piper Sandler lowered their target price on shares of Invitae to $1.50 and set an underweight rating for the company […] ....